Moderna Stock Cools After Cancer Vaccine Data Leak

Moderna's released phase 3 data for its cancer vaccine developed with Merck showed a 42% reduction in recurrence or death risk versus Keytruda. The stock fell 17% yesterday after the data was leaked and was down another 3.9% premarket, despite remaining up 587% year to date from its Oct. 21 four-year high of $254.48. Options positioning was unusually put-heavy: the 10-day put/call volume ratio was 0.98, above 95% of readings over the past year, and the SOIR was 1.63, near its annual high.

Analysis

The key issue is not the headline relative-risk reduction but whether the complete Phase 3 dataset supports a clinically meaningful, durable benefit with acceptable safety—and whether Moderna captures enough economics to justify its valuation. Verify absolute event rates, follow-up, subgroup consistency, adverse events, regulatory pathway, and the Moderna–Merck commercial terms before treating the result as a revenue catalyst. A strong relative endpoint alone does not establish launch timing, uptake, or profit contribution.

Near term (days to weeks), the unusually put-heavy positioning is a two-sided signal: it can amplify downside if investors conclude expectations outran the data, but it also creates squeeze risk if the full dataset removes concerns. The 30-day moving average is a flow reference, not fundamental support. After an exceptional year-to-date advance, even sound data may fail to prevent multiple compression if investors had priced in a cleaner or larger opportunity.

Over 1–3 months, detailed data, management commentary, and any regulatory or commercial updates should determine whether the selloff is a positioning reset or a reassessment of the asset. Over 6–18 months, success could strengthen the oncology-vaccine platform and competitive position, but also raises execution and manufacturing demands; competitors’ pipelines and standard-of-care changes could limit uptake. Merck may participate through the collaboration, but its share of economics is not established here. Contrarian point: elevated put activity is not proof of informed bearishness, and the reported efficacy signal may be underappreciated—but neither warrants buying before checking the absolute benefit and deal economics.

Key Decisions for Investors

• Do not chase MRNA immediately. Set a review trigger for publication or presentation of the complete dataset and verify absolute recurrence/death rates, safety, follow-up, and the Moderna–Merck economics; absent those details, keep the event on watch rather than assigning a sales forecast.
• For investors seeking defined-risk upside, consider a small MRNA call spread only after the data are independently digested and price action stabilizes; the debit is the maximum loss, while the spread caps gains. Avoid naked short puts: crowded put positioning can unwind sharply on positive clarification.
• Treat a sustained break below the 30-day moving average as a tactical warning, not a standalone short signal. Reassess bearish exposure if the full dataset supports a robust absolute benefit; the thesis is falsified by materially weaker absolute efficacy, concerning safety, or management commentary that pushes commercialization materially out.
• Do not infer a material near-term earnings benefit for MRK without verified collaboration economics and launch timing. Track regulatory milestones and the agreement terms before positioning MRK on this read-through.